Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Gregory E. Otteson
Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma
Dear Editor, Multiple myeloma (MM) is characterized by substantial biological heterogeneity, with outcomes influenced by baseline disease characteristics and depth of response to therapy [1]. Measurable residual disease (MRD) has emerged as a powerful post-treatment prognostic marker; however, assessment of residual disease burden does not directly characterize the proliferative behavior of the remaining clonal plasma cells [2].
Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia
Abstract Flow cytometry (FC) is essential for detecting measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), but its use is limited by the expertise and time required for manual analysis. We developed an artificial intelligence (AI) pipeline, Clustering/Classification of All Events, Dimensionality reduction, Downsampling, and Aberrancy Scaling (CCADDAS), to automatically enhance raw FC files, streamlining CLL MRD detection using a single-tube 10-color panel.
Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia - Leukemia
Correction to: Leukemia https://doi.org/10.1038/s41375-025-02653-z, published online 26 May 2025 1. On page 1, column 2, line 4 of the published PDF, the text should read:“wherein PBMC% in most cases is the sum of monocyte and lymphocyte percentages.”instead of the current version:“wherein PBMC% is the sum of monocyte and neutrophil percentages.” 2. In Figure 1, an asterisk (*) appears in the figure, but the corresponding explanatory footnote is missing in the published version.
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid Leukemia
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
FDA IDE validation of multiple myeloma MRD test by flow cytometry
To the Editor: Two recent decisions by the Food and Drug Administration will likely significantly impact testing for multiple myeloma (MM) minimal residual disease (MRD).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Gregory E.
Contact Gregory E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack